INITIALISE will provide an unprecedented in-depth overview of how the immune systems develops pre- and postnatally, how the specific exogenous and endogenous factors shape it, and how they together contribute to risks of specific adverse health outcomes.
INITIALISE will include multiple health outcomes in the design of longitudinal multiomics studies. This will provide comprehensive overviews of which environmental, genetic and host phenotypic factors are disease-specific, and which are generally associated with poor health outcomes later in life.
INITIALISE will set up a clinical demonstrator study where infants will be stratified based on their risk profile, then randomised into treatment or placebo. We will establish panels of biomarkers associated with outcomes across the three INITIALISE domains. The specific intervention to be used will be selected towards the end of the second year of the project.